ArticleAmerican journal of respiratory and critical care medicine2010
Identification of lipocalin and apolipoprotein A1 as biomarkers of chronic obstructive pulmonary disease.
Article in American journal of respiratory and critical care medicine, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 32 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
32 citing papers in PubMed, 1 synthesis or guideline pooled it, 75 citations in OpenAlex.
- Evaluation of common protein biomarkers involved in the pathogenesis of respiratory diseases with proteomic methods: A systematic review.Immunity, inflammation and disease · 2023Pooled it
- Proteomic profiling of lung immune cells reveals dysregulation of phagocytotic pathways in female-dominated molecular COPD phenotype.Respiratory research · 2018Trial
- Associations between serum lipid profiles and the incidence of chronic obstructive pulmonary disease in the UK Biobank.Journal of health, population, and nutrition · 2025Article
- Multi-omics characterization of early chronic obstructive pulmonary disease.Respiratory research · 2025Article
- Longitudinal analysis of adiponectin to leptin and apolipoprotein B to A1 ratios as markers of future airflow obstruction and lung function decline.Scientific reports · 2024Observational
- Blood Adipokines/Cytokines in Young People with Chronic Bronchitis and Abdominal Obesity.Biomolecules · 2022Article
- Proteomic Network Analysis of Bronchoalveolar Lavage Fluid in Ex-Smokers to Discover Implicated Protein Targets and Novel Drug Treatments for Chronic Obstructive Pulmonary Disease.Pharmaceuticals (Basel, Switzerland) · 2022Article
- Immunomodulatory regulator blockade in a viral exacerbation model of severe asthma.Frontiers in immunology · 2022Article
- Differential Expression of Serum Proteins in Chronic Obstructive Pulmonary Disease Assessed Using Label-Free Proteomics and Bioinformatics Analyses.International journal of chronic obstructive pulmonary disease · 2022Article
- HDL and Therapy.Advances in experimental medicine and biology · 2022Article
- Protein Biomarkers for COPD Outcomes.Chest · 2021Review
- Tear Lipocalin and Lipocalin-Interacting Membrane Receptor.Frontiers in physiology · 2021Article
- High-Density Lipoprotein (HDL) in Allergy and Skin Diseases: Focus on Immunomodulating Functions.Biomedicines · 2020Review
- Lipocalin-1 Expression as a Prognosticator Marker of Survival in Breast Cancer Patients.Breast care (Basel, Switzerland) · 2020Article
- Article
- Association of innate defense proteins BPIFA1 and BPIFB1 with disease severity in COPD.International journal of chronic obstructive pulmonary disease · 2018Article
- New Strategies and Challenges in Lung Proteomics and Metabolomics. An Official American Thoracic Society Workshop Report.Annals of the American Thoracic Society · 2017Article
- Article
- Ability of salivary biomarkers in the prognostic of systemic and buccal inflammation.Journal of clinical and experimental dentistry · 2017Review
- Examining the role of ABC lipid transporters in pulmonary lipid homeostasis and inflammation.Respiratory research · 2017Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
15 authors at 5 institutions in 2 countries.
Funding
Abstract
rationaleMuch effort is being made to discover noninvasive biomarkers of chronic airway disease that might enable better management, predict prognosis, and provide new therapeutic targets.
objectivesTo undertake a comprehensive, unbiased proteomic analysis of induced sputum and identify novel noninvasive biomarkers for chronic obstructive pulmonary disease (COPD).
methodsInduced sputum was obtained from patients with COPD with a spectrum of disease severity and from control subjects. Two-dimensional gel electrophoresis and mass spectrometric identification of differentially expressed proteins were first applied to induced sputum from patients with GOLD stage 2 COPD and healthy smoker control subjects. Initial results thus obtained were validated by a combination of immunoassays (Western blotting and ELISA) applied to a large subject cohort. The biomarkers were localized to bronchial mucosa by immunohistochemistry. MEASUREMENTS AND MAIN
resultsOf 1,325 individual protein spots identified, 37 were quantitatively and 3 qualitatively different between the two groups (P < 0.05%). Forty protein spots were subjected to tandem mass spectrometry, which identified 15 separate protein species. Seven of these were further quantified in induced sputum from 97 individuals. Using this sequential approach, two of these potential biomarkers (apolipoprotein A1 and lipocalin-1) were found to be significantly reduced in patients with COPD when compared with healthy smokers. Their levels correlated with FEV(1)/FVC, indicating their relationship to disease severity.
conclusionsA potential role for apolipoprotein A1 and lipocalin-1 in innate defense has been postulated previously; our discovery of their reduction in COPD indicates a deficient innate defense system in airway disease that could explain increased susceptibility to infectious exacerbations.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.